Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long-Acting Opioid REMS Tally: FDA Lists 12 Brand, 23 Generic

Executive Summary

Nineteen companies will implement individual Risk Evaluation and Mitigation Strategies for long-acting/extended-release opioid products that are subject to the class-wide REMS unveiled by FDA July 9.

Advertisement

Related Content

Depomed To Make Treasure Out of J&J Trash With Nucynta Buy
FDA Rejects Endo’s Deadline On Opana ER Petition; Impax Product May Become New RLD
Brand And Generic Opioid Makers Agree: FDA Should Issue Guidance On Tamper Resistance
Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
Opioid Training Syllabus Increases Emphasis On Patient Monitoring In Final REMS Blueprint
Mandatory Training For Opioid Prescribers Remains Stuck On Drawing Board
One-Page MedGuide For Long-acting Opioids Sets Stage For Retooling MedGuide Format
At-Risk Launches: Three Cases May Determine How Damages Are Calculated

Topics

Advertisement
UsernamePublicRestriction

Register

PS054592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel